More than 3½ years ago, a potential link between exposure to gadolinium-based contrast agents (Gd-CA) and the development of nephrogenic systemic fibrosis (NSF) was proposed (1, 2) . Since then, daily radiologic practice has changed. Some radiologists refuse to give patients with a glomerular filtration rate (GFR) below 30 or 60 ml/min/1.73 m 2 an enhanced magnetic resonance imaging (MRI) examination and refer them to enhanced computed tomography (CT). Others just do an unenhanced MRI, while several radiologists do enhanced MRI with a more stable agent (e.g., macrocyclic agents) when the unenhanced images or the clinical history indicate the need for administration of a Gd-CA. Only very few continue the practice as if they had never heard of NSF and the stability of various Gd-CA. The real consequences of transferring a patient with reduced renal function from enhanced MRI to enhanced CT are seldom discussed, and the issue is not without its problems. It seems as if no one advocates any longer the use of Gd-CA for conventional X-ray and CT, in order to protect the kidneys from contrast-induced nephropathy (CIN). Therefore, this issue is not discussed in the current editorial.
In the workup of several diseases, CT is inferior to MRI from a diagnostic point of view. In particular, when it comes to the central nervous system (CNS), the spine, and osteoarticular pathology, MRI is superior (3) . Also, within the abdomen, enhanced MRI has some advantages compared to enhanced CT. Thus, transfer to enhanced CT in fear of NSF may expose the patient to an inferior diagnostic workup. Recently, a case was presented to us by a Scandinavian colleague. A patient was referred to CT urography due to a single episode of macroscopic hematuria. The doctor in charge of the CT scanner refused to give the patient an iodinebased contrast agent (I-CA) because of the increased risk of CIN, and referred the patient to enhanced MRI. The patient had chronic kidney disease stage 5 but was not yet on replacement therapy. The doctor at the MR unit also refused to give the patient an enhanced examination, but this time because of the risk of NSF. There were some calcifications in the left pelvic cavity, and the unenhanced scans were reported as showing pelvic stones. Four months later, the patient returned after a new episode of macroscopic hematuria. This time, enhanced MRI was performed. It revealed that it was not pelvic stones, but a urothelial tumor with calcifications in the pelvic cavity. However, this time, the patient also had metastases from the urothelial tumor. Thus, it is not appropriate any longer to talk about CIN and NSF; ''metastases'' (delay of diagnosing a malignant lesion) have to be included as a third alternative.
Radiation from the CT scanner is also an issue, particularly in young patients who have a higher risk of developing a solid cancer from the radiation than older patients (4). Thus, in young patients, this must also be taken into consideration.
Severe anaphylactoid-like reactions are believed to occur more frequently after I-CA than after Gd-CA (5). However, comparative studies have never been performed. Recently, an American colleague drew our attention to a case. The patient had chronic kidney disease stage 4 or 5. She was referred from enhanced MRI to enhanced CT due to fear of NSF; the department had decided no longer to give Gd-CA to patients with a glomerular filtration rate below 30 ml/min/1.73 m 2 . During the injection of the I-CA, the patient had an anaphylactoid-like reaction that required instant treatment. The patient did not survive the acute non-renal adverse reaction. Recent surveys have shown that radiologists and technicians are often not prepared for such events (6, 7) . They do not know where the adrenalin ACTA RADIOLOGICA is, the optimal dose of adrenalin, optimal instant procedures as well as the telephone number of the resuscitation team. Adverse reactions to contrast media also have to be taken into consideration.
Finally, one has to take into consideration the morbidity and mortality related to long-term hemodialysis (9 hours) in a patient who does not undergo regular hemodialysis (8) . It has been recommended to remove both I-and Gd-CA as soon as possible after injection in patients on hemodialysis, continuous peritoneal dialysis, or on conservative treatment. However, the hearts of patients belonging to the two latter groups are not used to hemodialysis and a dialysis catheter has to be inserted. Nine hours of dialysis are required to remove most contrast agents. The risk of complications due to dialysis and catheterization has to be included as well.
When it comes to CIN, it has to be admitted that the overwhelming majority of the literature derives from cardiac investigations, e.g., coronary angiography, and only very limited knowledge about the consequences of intravenous injection is available (9, 10) . Furthermore, there are almost no studies involving chronic kidney disease stage 5 patients. The average risk of contrast-induced nephropathy based on several comparative studies (dimer vs. various monomers) is around 5% in patients with chronic kidney disease stage 3 and 4 (9, 10). The risk of contrast-induced nephropathy increases with decreasing renal function. A prevalence of contrast-induced nephropathy of 10% in patients with chronic kidney disease stage 5 does not seem to be inappropriate. As a temporary decrease in glomerular filtration rate is correlated with an increased morbidity and mortality seen over 1 to 2 years, this also has to be taken into consideration (10Á12).
A 100% NSF-safe Gd-CA may not exist, but there are agents that are correlated with a lower prevalence than other agents. A case of NSF in which the patient has only been exposed to a single macrocyclic Gd-CA has never been published in the peer-reviewed literature, whereas multiple cases have been reported after exposure to less stable agents (13) . The prevalence of NSF is probably close to zero for macrocyclic agents (low-risk NSF agents in the European classification (14) ). For various high-risk NSF agents, the prevalence seems to differ, indicating a difference in prevalence between ionic and nonionic linear chelates (15) . A prevalence of around 5Á6% for nonionic linear agents has been reported, but then diagnosis was based on a review of the various registries and not inspection of each exposed patient (16) .
NSF is not an all-or-nothing disease. It appears in various stages, from death and nearly complete disability to small plaques on the lower extremities (17) . It is difficult to overlook severely disabled patients, but that is not the same as referring them to a rheumatologist, dermatologist, pathologist, etc. for diagnosis. These specialists will only have such patients in their registries if somebody has referred the patient or the patient has presented him-or herself to the doctor. Lighter lesions require a careful inspection of the skin. To date, only two groups have published a systematic review of their patients (18, 19) . Based on a systematic review, the prevalence of NSF turned out to be much higher, namely between 12 and 30%, and higher after two injections than after one injection. Todd et al. (19) , based on data collected prior to the report of a link between exposure to Gd-CA and the development of NSF, reported that patients with NSF had increased mortality compared to patients without NSF. Both regarding CIN and NSF, one has to admit that patients with severely reduced renal function have an increased mortality, and it is difficult to conclude whether death occurs ''naturally'' or is stimulated by exposure to a contrast agent. However, this is the same problem for both Iand Gd-CA (CIN/NSF). Accepting that there is no prospective randomized trial of CIN versus NSF in patients with severely reduced renal function or on replacement therapy, it seems appropriate to make assumptions. It seems that the prevalence of CIN after any nonionic I-CA given intravenously is at the same level as the prevalence of NSF (all stages taken together) after exposure to a nonionic linear Gd-CA. Long-term morbidity and mortality do not seem to differ significantly between the two entities. In this assumption, the prevalence of inferior diagnosis (''metastases''), the effect of radiation, and the risk of anaphylactoid reactions have not been taken into consideration. Based on our current knowledge, it seems that enhanced MRI with a lowrisk NSF agent is safer for a patient with severely reduced renal function or on replacement therapy with water production than an enhanced CT with a nonionic agent. Only in patients with zero water/ urine production does enhanced CT seem to be safer if it is diagnostically superior to MRI. It does not seem appropriate to deny a patient clinically well-indicated enhanced MRI as well as referring the patient to enhanced CT.
When you advise patients with reduced renal function or on dialysis, you should not only take NSF and CIN into consideration. Other important factors, such as acute non-renal adverse reactions (e.g., anaphylactoid reactions), complications due to dialysis and catheterization, the harmful effects of radiation, and the risk of overlooking a lesion due to inferior diagnostic workup, should also be taken into account.
At the bottom line, it is still under discussion whether NSF is correlated to exposure to Gd-CA, as it has been claimed that it occurs despite exposure (20) ; these patients did not have their tissue examined for gadolinium. Regarding CIN, some believe that it is only due to natural fluctuations in serum creatinine levels and is unrelated to the exposure to I-CA (21) . However, the evidence is not yet in for those views. Until proven, we must do our utmost to avoid CIN and NSF.
No patient, regardless of renal function, should have an injection of I-or Gd-CA if there is no good clinical indication (e.g., macroscopic hematuria) and/or a suspicious finding on unenhanced scan (e.g. inhomogeneous lesion in the kidney) and, even then, only the smallest amount necessary to reach a diagnostic result should be used. 
